A Distinct Lipid Metabolism Signature of Acute Myeloid Leukemia with Prognostic Value

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Aug 12

PMID 35957912

Authors

Ding Li

Jiaming Liang

Wei Yang

Wenbin Guo

Wenping Song

Wenzhou Zhang

Xuan Wu

Baoxia He

Affiliations

Soon will be listed here.

Abstract

Background: Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy characterized by extensive genetic abnormalities that might affect the prognosis and provide potential drug targets for treatment. Reprogramming of lipid metabolism plays important roles in tumorigenesis and progression and has been newly recognized a new hallmark of malignancy, and some related molecules in the signal pathways could be prognostic biomarkers and potential therapeutic targets for cancer treatment. However, the clinical value of lipid metabolism reprogramming in AML has not been systematically explored. In this study, we aim to explore the clinical value of lipid metabolism reprogramming and develop a prognostic risk signature for AML.

Methods: We implemented univariate Cox regression analysis to identify the prognosis-related lipid metabolism genes, and then performed LASSO analysis to develop the risk signature with six lipid metabolism-related genes (LDLRAP1, PNPLA6, DGKA, PLA2G4A, CBR1, and EBP). The risk scores of samples were calculated and divided into low- and high-risk groups by the median risk score.

Results: Survival analysis showed the high-risk group hold the significantly poorer outcomes than the low-risk group. The signature was validated in the GEO datasets and displayed a robust prognostic value in the stratification analysis. Multivariate analysis revealed the signature was an independent prognostic factor for AML patients and could serve as a potential prognostic biomarker in clinical evaluation. Furthermore, the risk signature was also found to be closely related to immune landscape and immunotherapy response in AML.

Conclusions: Overall, we conducted a comprehensive analysis of lipid metabolism in AML and constructed a risk signature with six genes related to lipid metabolism for the malignancy, prognosis, and immune landscape of AML, and our study might contribute to better understanding in the use of metabolites and metabolic pathways as the potential prognostic biomarkers and therapeutic targets for AML.

Citing Articles

Identifying cancer prognosis genes through causal learning.

Wu S, Yin C, Wang Y, Sun H Brief Bioinform. 2025; 26(1.

PMID: 39808115 PMC: 11729728. DOI: 10.1093/bib/bbae721.

Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia Classification and Metabolic Characteristics for Informing and Advancing Treatment.

Wemyss C, Jones E, Stentz R, Carding S Cancers (Basel). 2025; 16(24.

PMID: 39766036 PMC: 11675077. DOI: 10.3390/cancers16244136.

RummaGEO: Automatic mining of human and mouse gene sets from GEO.

Marino G, Clarke D, Lachmann A, Deng E, Maayan A Patterns (N Y). 2024; 5(10):101072.

PMID: 39569206 PMC: 11573963. DOI: 10.1016/j.patter.2024.101072.

Lipid metabolism-related gene signature predicts prognosis and unveils novel anti-tumor drugs in specific type of diffuse large B cell lymphoma.

Wang C, Zhang R, Zhang H, Gao H, Zhu Y, Jiao L Mol Med. 2024; 30(1):210.

PMID: 39538125 PMC: 11559131. DOI: 10.1186/s10020-024-00988-4.

Prognostic implications of metabolism-related genes in acute myeloid leukemia.

Ren N, Wang J, Li R, Yin C, Li M, Wang C Front Genet. 2024; 15:1424365.

PMID: 39421301 PMC: 11484252. DOI: 10.3389/fgene.2024.1424365.

References

Prada-Arismendy J, Arroyave J, Rothlisberger S . Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2016; 31(1):63-76. DOI: 10.1016/j.blre.2016.08.005. View

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

Olmez I, Love S, Xiao A, Manigat L, Randolph P, McKenna B . Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol. 2017; 20(2):192-202. PMC: 5777487. DOI: 10.1093/neuonc/nox119. View

Martinez-Reyes I, Chandel N . Cancer metabolism: looking forward. Nat Rev Cancer. 2021; 21(10):669-680. DOI: 10.1038/s41568-021-00378-6. View

Cohen J, Li L, Wang Y, Thoburn C, Afsari B, Danilova L . Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018; 359(6378):926-930. PMC: 6080308. DOI: 10.1126/science.aar3247. View

Delaidelli A, Dunham C, Santi M, Negri G, Triscott J, Zheludkova O . Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. Clin Cancer Res. 2021; 28(1):116-128. DOI: 10.1158/1078-0432.CCR-21-2057. View

Zhang W, Wang X, Zhang L, Geng D, Wang Y, Sun D . Inhibition of PLA2G4A Reduces the Expression of Lung Cancer-Related Cytokines. DNA Cell Biol. 2018; . DOI: 10.1089/dna.2018.4286. View

Bai H, Zhou M, Zeng M, Han L . Is a Potential Biomarker Predicting Shorter Overall Survival in Patients with Non-M3/ Wildtype Acute Myeloid Leukemia. DNA Cell Biol. 2020; 39(4):700-708. DOI: 10.1089/dna.2019.5187. View

Takeishi K, Taketomi A, Shirabe K, Toshima T, Motomura T, Ikegami T . Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway. J Hepatol. 2012; 57(1):77-83. DOI: 10.1016/j.jhep.2012.02.026. View

10.

Henderson R, OKane M, McGilligan V, Watterson S . The genetics and screening of familial hypercholesterolaemia. J Biomed Sci. 2016; 23:39. PMC: 4833930. DOI: 10.1186/s12929-016-0256-1. View

11.

Newell L, Cook R . Advances in acute myeloid leukemia. BMJ. 2021; 375:n2026. DOI: 10.1136/bmj.n2026. View

12.

Hassan J, Lieske A, Dorpmund N, Klatt D, Hoffmann D, Kleppa M . A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML. Int J Mol Sci. 2021; 22(17). PMC: 8431012. DOI: 10.3390/ijms22179411. View

13.

Ha M, Han M, Kim J, Jeong D, Oh S, Kim Y . Prognostic role of TPD52 in acute myeloid leukemia: A retrospective multicohort analysis. J Cell Biochem. 2018; 120(3):3672-3678. DOI: 10.1002/jcb.27645. View

14.

Fernandez L, Gomez de Cedron M, Ramirez de Molina A . Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment. Front Oncol. 2020; 10:577420. PMC: 7655926. DOI: 10.3389/fonc.2020.577420. View

15.

Zhang J, Song Y, Shi Q, Fu L . Research progress on FASN and MGLL in the regulation of abnormal lipid metabolism and the relationship between tumor invasion and metastasis. Front Med. 2021; 15(5):649-656. DOI: 10.1007/s11684-021-0830-0. View

16.

Jo A, Choi T, Jo Y, Jyothi K, Nguyen M, Kim J . Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment. Antioxid Redox Signal. 2016; 26(2):70-83. DOI: 10.1089/ars.2015.6457. View

17.

Mullard A . Cancer metabolism pipeline breaks new ground. Nat Rev Drug Discov. 2016; 15(11):735-737. DOI: 10.1038/nrd.2016.223. View

18.

Kayser S, Levis M . Clinical implications of molecular markers in acute myeloid leukemia. Eur J Haematol. 2018; 102(1):20-35. PMC: 7883114. DOI: 10.1111/ejh.13172. View

19.

Purow B . Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer. Clin Cancer Res. 2015; 21(22):5008-12. PMC: 4644682. DOI: 10.1158/1078-0432.CCR-15-0413. View

20.

Li J, Pan C, Boese A, Kang J, Umano A, Magliocca K . DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling. Clin Cancer Res. 2020; 26(14):3843-3855. PMC: 7367757. DOI: 10.1158/1078-0432.CCR-19-3790. View